Second @entity5 (SPMs) are issues for @entity1 with @entity1582 ( @entity1582 ). There may have been some limitations in prior studies, such as difficulties in a longer follow-up and absence of established screening methods. Therefore, we studied autopsied cases to overcome these limitations. This study aimed to examine SPMs using autopsy reports. Ninety-one cases of @entity1582 autopsied at our institution from 1979 to 2013 were analyzed. Median age of autopsied @entity1 was 64.1 years, and proportion of male/female was 59/32. Autopsy was performed in 35.3% of @entity1 died of @entity1582 . There were five cases of SPMs with a median confirmation time of 38 (12-132) months from the diagnosis of @entity1582 . In three of the five @entity1 , the diagnosis of SPMs was established at autopsy. One case was of @entity2590 , and the others were of non-hematological @entity5 . The annual risk of @entity10417 estimated using the Kaplan-Meier method was approximately 1%. Three of five @entity10417 cases were detected at autopsy. Analysis of autopsy may contribute to estimate the actual risk of SPMs in @entity1582 .

Autopsy Analysis may Contribute to Establish Actual Incidence of Second Primary XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity10417 :: ('MESH:C567481', 'Disease') :: ['SPM'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary malignancies', 'malignancies'] @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['multiple myeloma', 'MM']
@entity5 :: (MESH:D009369,Disease) :: ['Malignancies in Myeloma']
